Human polyomavirus JC (JCV) infection of luman B lymphocytes: A possible mechanism for JCV transmigration across the blood-brain barrier

Journal of Infectious Diseases

Volumn 202, Issue 2, 2010, Pages 184-191

  Chapagain, Moti L ^a   Nerurkar, Vivek R ^a  

^a UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBONUCLEASE; FLUORESCEIN ISOTHIOCYANATE; MESSENGER RNA; VIRUS RNA; VIRUS DNA;

ARTICLE; B LYMPHOCYTE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FETUS; GLIA CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; JC VIRUS; NONHUMAN; POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; VIRION; VIRUS ENTRY; VIRUS GENE; VIRUS REPLICATION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; BRAIN; DEMYELINATING DISEASE; DISEASE TRANSMISSION; FLUORESCENCE MICROSCOPY; GENETIC TRANSCRIPTION; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; KIDNEY; LYMPHOID TISSUE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; VIROLOGY; VIRUS CELL TRANSFORMATION; VIRUS GENOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; B-LYMPHOCYTES; BLOOD-BRAIN BARRIER; BRAIN; CELL TRANSFORMATION, VIRAL; DEMYELINATING DISEASES; DEOXYRIBONUCLEASES; DNA, VIRAL; FLUORESCEIN-5-ISOTHIOCYANATE; GENOME, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; JC VIRUS; KIDNEY; LYMPHOID TISSUE; MICROSCOPY, FLUORESCENCE; POLYMERASE CHAIN REACTION; POLYOMAVIRUS INFECTIONS; RNA, MESSENGER; RNA, VIRAL; TRANSCRIPTION, GENETIC;

EID: 77954594238     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/653823     Document Type: Article

References (44)

1. Astrom KE, Mancall EL, Richardson EP Jr. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 1958; 81: 93-111.
2. Frisque RJ, White FA III. The molecular biology of JC virus, causative agent of progressive multifocal leukoencephalopathy. In: P. RR, ed. Molecular neurovirology. Totowa, NJ: Humana Press, 1992:25-158.
3. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971; 1:1257-1260.
4. Richardson EP Jr. Our evolving understanding of progressive multifocal leukoencephalopathy. Ann N Y Acad Sci 1974; 230:358-364.
5. Doerries K. Human Polyomavirus JC and BK persistent infection. In: Ahsan N, ed. Polyomaviruses and human diseases. Vol.577: Springer Science and Landes Bioscience, 2006:102-116.
6. Dorries K, Vogel E, Gunther S, Czub S. Infection of human polyomaviruses JC and BK in peripheral blood leukocytes from immunocompetent individuals. Virology 1994; 198:59-70.
7. Major EO, Amemiya K, Tornatore CS, Houff SA, Berger JR. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 1992; 5:49-73.
8. Monaco MC, Jensen PN, Hou J, Durham LC, Major EO. Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection. J Virol 1998; 72:9918-9923.
9. Monaco MC, Shin J, Major EO. JC virus infection in cells from lymphoid tissue. Dev Biol Stand 1998; 94:115-122.
10. Tornatore C, Berger JR, Houff SA, et al. Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy. Ann Neurol 1992; 31:454-462.
11. White FA III, Ishaq M, Stoner GL, Frisque RJ. JC virus DNA is present in many human brain samples from patients without progressive multifocal leukoencephalopathy. J Virol 1992; 66:5726-5734.
12. Monaco MC, Atwood WJ, Gravell M, Tornatore CS, Major EO. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol 1996; 70:7004-7012.
13. Newman JT, Frisque RJ. Detection of archetype and rearranged variants of JC virus in multiple tissues from a pediatric PML patient. J Med Virol 1997; 52:243-252.
14. Houff SA, Berger JR. The bone marrow, B cells, and JC virus. J Neurovirol 2008; 14:341-343.
15. Houff SA, Major EO, Katz DA, et al. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 1988; 318:301-305.
16. Marzocchetti A, Wuthrich C, Tan CS, et al. Rearrangement of the JC virus regulatory region sequence in the bone marrow of a patient with rheumatoid arthritis and progressive multifocal leukoencephalopathy. J Neurovirol 2008; 14:455-458.
17. Sabath BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis 2002; 186(suppl 2):S180-S186.
18. Wei G, Liu CK, Atwood WJ. JC virus binds to primary human glial cells, tonsillar stromal cells, and B-lymphocytes, but not to T lymphocytes. J Neurovirol 2000; 6:127-136.
19. Major EO, Amemiya K, Elder G, Houff SA. Glial cells of the human developing brain and B cells of the immune system share a common DNA binding factor for recognition of the regulatory sequences of the human polyomavirus, JCV. J Neurosci Res 1990; 27:461-471.
20. Atwood WJ, Amemiya K, Traub R, Harms J, Major EO. Interaction of the human polyomavirus, JCV, with human B-lymphocytes. Virology 1992; 190:716-723.
21. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353:369-374.
22. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353:375-381.
23. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353:362-368.
24. Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005; 64:1336-1342.
25. Arroyo AG, Yang JT, Rayburn H, Hynes RO. Differential requirements for alpha4 integrins during fetal and adult hematopoiesis. Cell 1996; 85:997-1008.
26. Ransohoff RM. Natalizumab and PML. Nat Neurosci 2005; 8:1275.
27. Ransohoff RM. "Thinking without thinking" about natalizumab and PML. J Neurol Sci 2007; 259:50-52.
28. Genetech. Important drug warning regarding Raptiva (efalizumab). Available at: http://www.gene.com/gene/products/information/pdf/raptiva-dhcp- 0309.pdf. Accessed 10 April 2009.
29. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46:1-23; quiz, 23-26.
30. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004-2013.
31. Chapagain ML, Nguyen T, Bui T, Verma S, Nerurkar VR. Comparison of real-time PCR and hemagglutination assay for quantitation of human polyomavirus JC. Virol J 2006; 3:3.
32. Chapagain ML, Verma S, Mercier F, Yanagihara R, Nerurkar VR. Polyomavirus JC infects human brain microvascular endothelial cells independent of serotonin receptor 2A. Virology 2007; 364:55-63.
33. Co JK, Verma S, Gurjav U, Sumibcay L, Nerurkar VR. Interferon- alpha and- beta restrict polyomavirus JC replication in primary human fetal glial cells: implications for progressive multifocal leukoencephalopathy therapy. J Infect Dis 2007; 196:712-718.
34. Verma S, Ziegler K, Ananthula P, et al. JC virus induces altered patterns of cellular gene expression: Interferon-inducible genes as major transcriptional targets. Virology 2006; 345:457-467.
35. Alter A, Duddy M, Hebert S, et al. Determinants of human B cell migration across brain endothelial cells. J Immunol 2003; 170:4497-4505.
36. Imrie A, Meeks J, Gurary A, et al. Differential functional avidity of dengue virus-specific T-cell clones for variant peptides representing heterologous and previously encountered serotypes. J Virol 2007; 81: 10081-10091.
37. Liu CK, Hope AP, Atwood WJ. The human polyomavirus, JCV, does not share receptor specificity with SV40 on human glial cells. J Neurovirol 1998; 4:49-58.
38. Liu CK, Wei G, Atwood WJ. Infection of glial cells by the human polyomavirus JC is mediated by an N-linked glycoprotein containing terminal alpha(2-6)-linked sialic acids. J Virol 1998; 72:4643-4649.
39. Chapagain ML, Sumibcay L, Gurjav U, Kaufusi PH, Kast RE, Nerurkar VR. Serotonin receptor 2A blocker (risperidone) has no effect on human polyomavirus JC infection of primary human fetal glial cells. J Neurovirol 2008; 14:448-454.
40. Newman JT, Frisque RJ. Identification of JC virus variants in multiple tissues of pediatric and adult PML patients. J Med Virol 1999; 58:79-86.
41. Tan CS, Dezube BJ, Bhargava P, et al. Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J Infect Dis 2009; 199:881-888.
42. Georgsson G. Neuropathologic aspects of lentiviral infections. Ann N Y Acad Sci 1994; 724:50-67.
43. Andreoletti L, Dubois V, Lescieux A, et al. Human polyomavirus JC latency and reactivation status in blood of HIV-1-positive immunocompromised patients with and without progressive multifocal leukoencephalopathy. AIDS 1999; 13:1469-1475.
44. Focosi D, Maggi F, Andreoli E, Lanini L, Ceccherini-Nelli L, Petrini M. The role of bone marrow cells for JCV pathogenicity. J Clin Virol 2009; 45:230-231.